Company intelligence / Profile preview

Inno BioScience

Seongnam, Gyeonggi-do, South Korea

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Inno BioScience is a South Korean clinical-stage biotechnology company focused on developing next-generation immuno-oncology therapies. The company specializes in bispecific antibodies and fusion proteins designed to overcome the limitations of current checkpoint inhibitors by simultaneously targeting multiple pathways in the tumor microenvironment. Its lead candidate, IB-01, is a PD-L1/TGF-beta trap bifunctional fusion protein aimed at treating various solid tumors. Inno BioScience leverages its proprietary platform to build a pipeline of multi-targeting agents, including combinations of PD-L1 with VEGF or 4-1BB.

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyMonoclonal antibodyRecombinant fusion protein
Industry: Biotech

Beyond the preview

Go deeper on Inno BioScience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inno BioScience.

Explore the full profile